Relevant bibliographies by topics / Benign prostatic hyperplasia

Academic literature on the topic 'Benign prostatic hyperplasia'

Author: Grafiati
Published: 4 June 2021
Last updated: 1 August 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Benign prostatic hyperplasia.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Benign prostatic hyperplasia"

1

Leedahl, David D., Phil H. Vo, Pamela M. Maxson, and Jenna K. Lovely. "Benign Prostatic Hyperplasia." Journal of Pharmacy Practice 26, no. 1 (July 13, 2012): 52–58. http://dx.doi.org/10.1177/0897190012451913.

Full text
Abstract:
This review provides an update on the treatment of benign prostatic hyperplasia and the pharmacologic considerations for perioperative care. By age 85 years, approximately 90% of men have prostate histologic characteristics consistent with benign prostatic hyperplasia. Pharmacologic treatment with an alpha1 receptor antagonist may reduce symptoms and, when given in combination with a 5-alpha-reductase inhibitor, may decrease the risk of urinary retention and the need for surgical intervention. Transurethral resection of the prostate has been the historical standard when surgical intervention is indicated. However, recent evidence suggests that Holmium laser enucleation of the prostate may have similar efficacy with less risk of complications and with decreased catheterization time. Prostatic urological operations may have perioperative complications, including urethral bleeding, acute urinary retention, urinary tract infection, urge incontinence, and venous thromboembolism. Pharmacist recommendations for the appropriate use of laxatives, antibiotics, anticoagulation, and urinary antispasmodics are key components of perioperative management. Surgical interventions improve symptoms but may have complications, providing the pharmacist an opportunity to improve perioperative care.
APA, Harvard, Vancouver, ISO, and other styles
2

Lorenzo, Guillermo, Thomas J. R. Hughes, Pablo Dominguez-Frojan, Alessandro Reali, and Hector Gomez. "Computer simulations suggest that prostate enlargement due to benign prostatic hyperplasia mechanically impedes prostate cancer growth." Proceedings of the National Academy of Sciences 116, no. 4 (January 7, 2019): 1152–61. http://dx.doi.org/10.1073/pnas.1815735116.

Full text
Abstract:
Prostate cancer and benign prostatic hyperplasia are common genitourinary diseases in aging men. Both pathologies may coexist and share numerous similarities, which have suggested several connections or some interplay between them. However, solid evidence confirming their existence is lacking. Recent studies on extensive series of prostatectomy specimens have shown that tumors originating in larger prostates present favorable pathological features. Hence, large prostates may exert a protective effect against prostate cancer. In this work, we propose a mechanical explanation for this phenomenon. The mechanical stress fields that originate as tumors enlarge have been shown to slow down their dynamics. Benign prostatic hyperplasia contributes to these mechanical stress fields, hence further restraining prostate cancer growth. We derived a tissue-scale, patient-specific mechanically coupled mathematical model to qualitatively investigate the mechanical interaction of prostate cancer and benign prostatic hyperplasia. This model was calibrated by studying the deformation caused by each disease independently. Our simulations show that a history of benign prostatic hyperplasia creates mechanical stress fields in the prostate that impede prostatic tumor growth and limit its invasiveness. The technology presented herein may assist physicians in the clinical management of benign prostate hyperplasia and prostate cancer by predicting pathological outcomes on a tissue-scale, patient-specific basis.
APA, Harvard, Vancouver, ISO, and other styles
3

Dülgeroğlu, Yakup, Gönül Erden, Musa Ekici, Ahmet Yeşilyurt, Öner Odabaş, Fatma Uçar, and Gülfer Öztürk. "Diagnostic efficiency of miR-21 and miR-34a serum levels in malign and benign prostate diseases." Yeni Üroloji Dergisi 16, no. 3 (October 22, 2021): 221–27. http://dx.doi.org/10.33719/yud.2021;16-3-865045.

Full text
Abstract:
Objective: In this study aimed to determine the diagnostic efficiency of miR-21 and miR-34a serum levels in the discrimination of benign prostatic hyperplasia, chronic prostatitis, and prostate cancer. Materials and Methods: Blood samples were taken from 70 patients (25 benign prostatic hyperplasias, 10 chronic prostatitides, and 35 prostate cancer) who underwent prostate needle biopsy. After obtaining serum under suitable conditions, RNA isolation, cDNA synthesis, and qRT-PCR analysis were performed using Qiagen brand kits on Rotor-Gene® Q (Qiagen, Germany) device. -∆Ct values ​​were calculated using RNU6 as a reference gene for normalization. -∆Ct values ​​were used in all statistical calculations. Results: It was observed that miR-21 serum levels were upregulated in chronic prostatitis and cancer groups compared to benign prostatic hyperplasia and the difference between the groups was statistically significant (p = 0.021 and p = 0.001, respectively). The specificity and sensitivity of miR-21 and miR-21/miR-34a combination was calculated as 56% and 86%; 84% and 71% in discriminating benign prostatic hyperplasia and prostate cancer groups, respectively. Conclusion: In this study, it has been shown that miR-21 and miR-21/miR-34a combination has diagnostic performance that can be a biomarker candidate in diagnosing prostate cancer. In addition, the presence of a gradual increase in chronic prostatitis and prostate cancer at miR-21 levels compared to benign prostatic hyperplasia suggests that inflammation and cancer transformation processes taking place at the molecular level are also reflected in the circulating microRNA profile. Keywords: Prostate cancer, Prostatitis, Benign prostatic hyperplasia, MicroRNA, Diagnostic efficiency
APA, Harvard, Vancouver, ISO, and other styles
4

Al-Bazzaz, Wishyar, Omar Alkhayat, and Ali AlKhayat. "Monotherapy versus combination therapy in the treatment of benign prostatic hyperplasia: A single center study." Zanco Journal of Medical Sciences 24, no. 3 (December 25, 2020): 333–37. http://dx.doi.org/10.15218/zjms.2020.039.

Full text
Abstract:
Background and objectives: Most benign prostatic hyperplasia patients do not present obvious indicators for surgical intervention, so most of these patients are treated initially with medical therapy. This study aimed to compare the incidence of acute urinary retention after treatment with monotherapy with the incidence after combination therapy and determine the need for surgery in both methods. Methods: This is a retrospective study of the medical records of 248 benign prostatic hyperplasia patients who had attended Rizgary Teaching Hospital from May 2012 to June 2017. These patients were divided into two groups of 138 and 110 patients who have been treated by 0.4 mg tamsulosin capsule once daily and 0.4 mg tamsulosin capsule plus 5mg finasteride tablet once daily, respectively. Benign prostatic hyperplasia outcomes (acute urinary retention, benign prostatic hyperplasia related surgery) were compared between these two groups according to prostate volume and serum prostate specific antigen. Results: The combined treatment had significantly reduced the incidence of acute urinary retention and benign prostatic hyperplasia related surgery than monotherapy (P = 0.006 and 0.044, respectively). Similarly, when prostate volume and prostate specific antigen were above the cutoff value, both acute urinary retention and benign prostatic hyperplasia related surgery were lower in the combination therapy group than the monotherapy group. Conclusion: Combined therapy (0.4 mg tamsulosin plus 5mg finasteride) was significantly superior to 0.4 mg tamsulosin alone in the reduction of the incidence of acute urinary retention and benign prostatic hyperplasia related surgery among benign prostatic hyperplasia patients. Keywords: Benign prostatic hyperplasia; Acute urinary retention; Benign prostatic hyperplasia related surgery; Prostate volume; Prostate specific antigen.
APA, Harvard, Vancouver, ISO, and other styles
5

Rahman, Md A., and H. Naushaba. "Impact of Finasteride on Stroma of Benign Hyperplasia of Prostate." Journal of Medical Science & Research 16, Number 1 (January 1, 2011): 3–8. http://dx.doi.org/10.47648/jmsr.2011.v1601.01.

Full text
Abstract:
Benign prostatic hyperplasia (13P11) is a hyperplastic process of the strontal and epithelial cells of the prostate due to effect of male sex hormone testosterone. Testosterone is the main male sex hormone, responsible for growth of sexual character and accessory sex organs. Despite its effectiveness as an male sex hormone, it causes benign prostatic hyperplasia (BM resulting in urinary dysfunction. On the other hand, finasteride. a 4-azastroid, inhibits the hyperplastic effect of testosterone and benign prostatic hyperplasia. The objective of the study was to observe the effects of finasteride on the stroma of testosterone induced prostatic hyperplasis in long Evans rats. This experimental study was carried out in the Department of Anatomy, Sir Salimullah Medical College, Dhaka from January to December 2006. Total 45 matured male long Evans rats of age 8-10 weeks and weighing 200-300 gm were used in this study. They were divided into three equal groups. Group A was vehicle (olive oil) control group, Group 13 was testosterone treated group and Group C was testosterone and finasteride treated group. The rats were sacrificed on the eleventh day. It was concluded that finasteride is an effective drug that successfully inhibits the testosterone induced prostatic hvperplasia.
APA, Harvard, Vancouver, ISO, and other styles
6

Mohammed Ridha Jawad and Ghaith Ali Jasim. "Biochemical and Histopathological evaluation of prostatic tissue under effect of Pterostilbene in benign prostatic hyperplasia rat model." Al Mustansiriyah Journal of Pharmaceutical Sciences 23, no. 2 (May 23, 2023): 196–213. http://dx.doi.org/10.32947/ajps.v23i2.1022.

Full text
Abstract:
Background: Benign prostatic hyperplasia [BPH] is the urologic condition that affects elderly men the most frequently Benign prostatic hyperplasia. Benign prostatic hyperplasia must be distinguished from lower urinary tract symptoms and benign prostatic enlargement. which refers to an enlarged prostate, benign prostatic hyperplasia is a purely histological term the development, maintenance, and secretory activity of the prostate and other sex-accessory tissues are stimulated by the presence of certain hormones and growth factors. the pathophysiology of Benign prostatic hyperplasia is significantly influenced by the activity of the enzyme 5α-reductase. It's important to remember that 5-αreductase is responsible for creating Dihydrotestosterone a stronger androgen. Pterostilbene Mostly found in blueberries and grapes and pterostilbene substance with a number of biological properties including anticancer properties. pterostilbene is a lipid-soluble molecule that exists in both cis and trans forms with the latter being more prevalent. The conventional medication for Benign prostatic hyperplasia utilized in this trial was finasteride which inhibits the 5α-reductase enzyme and lowers the amount of Dihydrotestosterone. Methods: Forty-eight male rats were divided into six groups; the control group consisted of eight rats who received subcutaneous injections of oil vehicle for a period of 42 days. The induction group consisted of eight rats who received subcutaneous injections of testosterone propionate for a period of fourteen days. The finasteride group consisted of eight rats who received finasteride 0.44 mg/kg by oral gavage for a period of twenty-eight days following the induction of Benign prostatic hyperplasia and Pterostilbene 200 group included 8 rats were given pterostilbene 200mg/kg by oral gavage for 28 days after 14 days of Benign prostatic hyperplasia induction. pterostilbene 100 group included 8 rats were given a pterostilbene 100mg/kg per day kg by oral gavage for 28 days after 14 days of induction Benign prostatic hyperplasia dose and the resveratrol group included 8 rats were given a resveratrol 100mg/kg per day kg by oral gavage for 28 days after 14 days of induction Benign prostatic hyperplasia After twenty-eight days. Results: Histological section of prostate Pterostilbene 200 were similar those in control negative revealed numerous variable sizes alveoli that filled with homogenous eosinophilic secretion, had normal epithelial and stromal tissue. Conclusion: Pterostilbene have a potent anti-proliferative effect by decrease the hyperplastic nodules for prostate and return epithelial cell to normal and have a very good scavenging activity for free radical [very good as antioxidant] in compare with Vitamin c and resveratrol. Aim of study: evaluate the effect of Pterostilbene as Anti proliferative on Benign prostatic hyperplasia and assess the antioxidant activity for Pterostilbene by DPPH Assay.
APA, Harvard, Vancouver, ISO, and other styles
7

Tang, Ruipeng, and Chuan Xiao. "Correlation between Prostatic Calculi and Benign Prostatic Hyperplasia." Journal of Endocrinology Research 2, no. 1 (February 6, 2021): 44. http://dx.doi.org/10.30564/jer.v2i1.2518.

Full text
Abstract:
Prostatic calculus is a common disease of the urinary system, Prostate stones are more common in middle-aged and elderly men, With the development of ultrasonic diagnosis, more and more patients with prostate stone were found in physical examination,According to research shows,The vast majority of patients with benign prostatic hyperplasia in the pathogenesis of examination was found to have prostate stones, but so far the correlation between prostate stones and benign prostatic hyperplasia is still not very clear,Benign prostatic hyperplasia is an important factor affecting the physical and mental health and quality of life of the elderly male, With an increasing trend of population aging in China more quickly, this problem is more and more outstanding, but also allows us to further study the relationship between prostate stones and benign prostatic hyperplasia.
APA, Harvard, Vancouver, ISO, and other styles
8

Roitberg, G. E., V. V. Astashov, K. G. Mkrtchyan, and A. A. Lomshakov. "Treatment of beneficial prostate hyperplasia of large sizes: traditional surgical, low-invasive and laser technologies (literature review)." Laser Medicine 24, no. 4 (April 28, 2021): 62–68. http://dx.doi.org/10.37895/2071-8004-2020-24-4-62-68.

Full text
Abstract:
Benign prostatic hyperplasia – one of the most common diseases in older men. The treatment strategy for benign prostatic hyperplasia consists in its drug therapy, or active surgical tactics. The indication for planned surgical treatment of benign prostatic hyperplasia is the progression of symptoms of the lower urinary tract, which are not amenable to drug correction. Men with a large prostate volume of more than 80 m3, with severe symptoms of the lower urinary tract, with a history of acute urinary retention episodes, represent a difficult group of patients in terms of choosing the tactics of surgical treatment. This article discusses the most common operations that are used in the treatment of benign prostatic hyperplasia (especially of large sizes): open adenectomy, transurethral resection of the prostate gland, enucleation of benign prostatic hyperplasia using a holmium laser, embolization of an artery of the prostate gland. Surgical treatment of benign prostatic hyperplasia requires an individual approach to the patient, taking into account his age, concomitant pathology and clinical symptoms.
APA, Harvard, Vancouver, ISO, and other styles
9

Kaplan, Steven A. "Benign Prostatic Hyperplasia." Journal of Urology 205, no. 4 (April 2021): 1199–201. http://dx.doi.org/10.1097/ju.0000000000001612.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Kaplan, Steven A. "Benign Prostatic Hyperplasia." Journal of Urology 205, no. 5 (May 2021): 1490–92. http://dx.doi.org/10.1097/ju.0000000000001665.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Benign prostatic hyperplasia"

1

Jia, Guang. "MR imaging biomarkers for benign prostatic hyperplasia pharmacotherapy." Columbus, Ohio : Ohio State University, 2006. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=osu1164686290.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ambrosini, Gina L. "Dietary risk factors for prostate cancer and benign prostatic hyperplasia." University of Western Australia. School of Population Health, 2008. http://theses.library.uwa.edu.au/adt-WU2008.0135.

Full text
Abstract:
[Truncated abstract] This thesis examines the potential role of dietary intake in the development of two common conditions affecting the prostate gland; prostate cancer and benign prostatic hyperplasia (BPH). Diet is of interest as a potential risk factor for prostate cancer because of geographical variations in prostate cancer incidence and increased prostate cancer risks associated with migration from Asian to western countries. Some geographical variation has been suggested for BPH, but this is less certain. However, both prostate cancer and BPH have potential links with diet through their positive associations with sex hormone levels, metabolic syndrome, increased insulin levels and chronic inflammation. In addition, zinc is an essential dietary micronutrient required for semen production in the prostate gland. The original work for this thesis is presented in six manuscripts of which, four have been published in peer-reviewed journals (at the time of thesis completion). BPH investigated in this thesis is defined as surgically-treated BPH. The following hypotheses were investigated. Regarding foods, nutrients and the risk of prostate cancer and BPH: 1. Increasing intakes of fruits, vegetables and zinc are inversely associated with the risk of prostate cancer and BPH 2. Increasing intakes of total fat and calcium are positively associated with the risk of prostate cancer and BPH. 3. Dietary patterns characterised by high meat, processed meat, calcium and fat content are positively associated with the risk of prostate cancer and BPH. 4. Dietary patterns characterised by high fruit and vegetable and low meat content are inversely associated with the risk of prostate cancer and BPH. v Regarding methodological issues related to the study of diet-disease relationships: 5. Dietary patterns (overall diet) elicited from principal components analysis yield stronger diet-disease associations than when studying isolated nutrients. 6. Remotely recalled dietary intake is reliable enough to be used in studies of chronic disease with long latency periods, such as prostate cancer and BPH. Methods: Data from two studies was used to address the hypotheses above. ... Based on the literature reviewed and the original work for this thesis, the most important dietary risk factors for prostate cancer and BPH appear to be those common to western style diets, i.e. diets high in red meat, processed meat, refined grains, dairy products, and low in fruit and vegetables. This type of diet is likely to result in marginal intakes of antioxidants and fibre, excess intakes of fat and possibly, moderate intakes of carcinogens associated with processed meat and meat cooked at high temperatures. These dietary factors have been linked with biomarkers of inflammation, and they support the hypotheses that chronic inflammation is involved in the development of both prostate cancer and BPH. In addition, this work builds on evidence that zinc is an important factor in prostate health. There is scope for more investigation into the reliability of dietary patterns and the use of nutrient patterns as an alternative to focussing on single food components. Further studies on the reliability of remote dietary intake would also be useful. Because of the latency of chronic disease, it can be theorised that remote dietary recall may uncover more robust diet-disease relationships.
APA, Harvard, Vancouver, ISO, and other styles
3

Woo, Henry Hyunshik. "Evolution of minimally invasive surgical treatments for benign prostatic obstruction." Thesis, The University of Sydney, 2016. http://hdl.handle.net/2123/15772.

Full text
Abstract:
Transurethral resection of the prostate (TURP) has been the established surgical gold standard for the treatment of prostatic obstruction due to benign prostatic hyperplasia(BPH). Prior to TURP, the mainstay of surgical treatment was open suprapubic prostatectomy (SPP), which carried a high risk of morbidity and mortality. TURP did not go through rigorous assessment of outcomes or comparison with SPP in order to become labeled as the gold standard. TURP is still a procedure with potential significant morbidity, particular with regard to hemorrhage and surgical misadventure. In the mid to late 1990’s, there began efforts to find less morbid alternatives to TURP. Most of these early attempts fell out of favour due to clinical outcomes failing to meet both surgeon and patient expectations. In the 2000’s newer alternative treatment options such as photoselective vaporization of the prostate (PVP) and the prostatic urethral lift (PUL) have emerged and have progressively been introduced into clinical practice. Studies of these technologies form the basis of this DMedSci thesis. The use of the green wave length laser (532nm) to perform PVP is shown in a series of manuscripts to demonstrate it’s effectiveness and morbidity in treating various populations of men with lower urinary tract symptoms due to BPH. PUL is a minimally invasive treatment that has been shown in this series of manuscripts to relieve urinary symptoms rapidly and without any deleterious effect on sexual function. Readers are taken through the journey of how this technology has progressed from first-in-man studies through to entry into mainstream clinical practice.
APA, Harvard, Vancouver, ISO, and other styles
4

Gilmore, Paul Edward. "Isolation and characterization of stem cell phenotype in benign prostatic hyperplasia and prostate cancer." Thesis, University of Manchester, 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.492891.

Full text
Abstract:
The prostate epithelial stem cell has been proposed as the primary origin of neoplastic change in prostate cancer. However, due to a lack of specific markers, such cells have been profoundly difficult to isolate. We propose that the Hoechst 33342 dye efflux assay 'Side Population' originally developed to isolate a stem cell enriched haemopoietic stem cell population from bone marrow provides a method for identifying the cancer stem cell origin in prostatic adenocarcinoma.
APA, Harvard, Vancouver, ISO, and other styles
5

Chan, Hin-cheong. "The psychometric evaluation of the Chinese version of the international prostate symptom score (IPSS)." Click to view the E-thesis via HKUTO, 2004. http://sunzi.lib.hku.hk/hkuto/record/B31972871.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Noble, Amanda Jane. "The alpha←1-andrenoceptor subtype mediating contraction of the lower urinary tract." Thesis, University of Sheffield, 1997. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.284384.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Xu, Kexin. "Identification and evaluation of specific marker proteins associated with human benign peostate [sic] hyperplasia /." Hong Kong : University of Hong Kong, 2002. http://sunzi.lib.hku.hk/hkuto/record.jsp?B25435863.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Fernandes, Ancilla W. "Evaluating diagnostic and treatment modalities in the management of benign prostatic hyperplasia in the Veterans Administration population." Morgantown, W. Va. : [West Virginia University Libraries], 2000. http://etd.wvu.edu/templates/showETD.cfm?recnum=1543.

Full text
Abstract:
Thesis (M.S.)--West Virginia University, 2000.
Title from document title page. Document formatted into pages; contains ix, 154 p. : ill. Includes abstract. Includes bibliographical references (p. 137-143).
APA, Harvard, Vancouver, ISO, and other styles
9

Tayeb, Mohammed Taher. "Genetic risk factors influencing the development of prostate cancer in patients with benign prostatic hyperplasia." Thesis, University of Aberdeen, 2002. http://digitool.abdn.ac.uk/R?func=search-advanced-go&find_code1=WSN&request1=AAIU154536.

Full text
Abstract:
The primary aim of this study is to assess the predictive value of six molecular markers in determining PRCa risk in patients with BPH. These molecular markers are: (A)- Two polymorphic repeats, (CAG)n and (GGN)n, in the androgen receptor (AR) gene; (B)- A single nucleotide polymorphism (SNP) in the (-290 A to G) 5' regulatory region of the CYP3A4 gene; (C)- Two SNPs (TaqI and FokI) in vitamin D receptor (VDR) gene; (D)- A SNP (Val655Ile) in the transmembrane domain coding region of HER2 gene. The study evaluated 28 patients who presented with PRCa at least 3 years and up to 15 years after the diagnosis of BPH and 56 matched patients with BPH who did not progress to PRCa over a comparable period. The results of this study showed that CYP3A4 variant genotype identified men with BPH who are at increased risk of developing PRCa (odds ratio 5.2, 95% CI = 1.8-14.3). Similar finding was also seen for VDR TaqI SNP, where TT genotype was associated with a significant 5 fold increase in the risk of developing PRCa in patients previously diagnosed with BPH. Tentative evidence of association between risk of developing PRCa and the variant genotype of HER2 and VDR FokI SNPs was also demonstrated, although the results were not statistically significant. The odds ratio of developing PRCa was 1.88, and 2.33 in BPH patients having HER2 Ile/Ile genotype and VDR FokI FF genotype respectively. This study also showed no evidence for association between the size of AR CAG and GGN repeats and the risk of the development of PRCa in patients with BPH. However, data of this study suggest that BPH patients with AR CAG instability have a 12 fold increase risk in development PRCa. These results provide a potential tool to assist prediction strategies for this important disease.
APA, Harvard, Vancouver, ISO, and other styles
10

Hallin, Anders. "Transurethral microwave thermotherapy of benign prostatic hyperplasia : a clinical and methodological evaluation /." Stockholm, 1997. http://diss.kib.ki.se/1997/91-628-2727-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Benign prostatic hyperplasia"

1

Petrovich, Zbigniew, and Luc Baert, eds. Benign Prostatic Hyperplasia. Berlin, Heidelberg: Springer Berlin Heidelberg, 1994. http://dx.doi.org/10.1007/978-3-642-78185-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Jakse, Gerhard, Christian Bouffioux, Jean de Leval, and Rudi A. Janknegt, eds. Benign Prostatic Hyperplasia. Berlin, Heidelberg: Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-77480-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kirby, Roger S. Benign prostatic hyperplasia. London: Gower Medical, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

J, Christmas Timothy, ed. Benign prostatic hyperplasia. London: Gower Medical Publishing, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

International Consultation on Benign Prostatic Hyperplasia (5th 2000 Paris, France). Benign prostatic hyperplasia. Edited by Chatelain C. (Chritian), World Health Organization, and International Union against Cancer. [England]: Health Publication, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Physicians, American College of, and Hearst/ABC Viacom, eds. Benign prostatic hyperplasia. Livingston, N.J: Burrells's [distributor], 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

National Institutes of Health (U.S.), ed. Prostate enlargement: Benign prostatic hyperplasia. Bethesda, Md: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

H, Rodgers Charles, National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases (U.S.). Division of Kidney, Urologic, and Hematologic Dieases., and National Institutes of Health (U.S.), eds. Benign prostatic hyperplasia.: A workshop. [Bethesda, Md.]: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Koshiba, Ken, Makoto Miki, Toshiro Terachi, and Toyoaki Uchida, eds. Treatment of Benign Prostatic Hyperplasia. Tokyo: Springer Japan, 2000. http://dx.doi.org/10.1007/978-4-431-68444-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

D, Chisholm Geoffrey, ed. Handbook on benign prostatic hyperplasia. New York: Raven Press, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Benign prostatic hyperplasia"

1

Good, Daniel W., Bashar Nahas, Simon Phipps, Rick Popert, Jens-Uwe Stolzenburg, and Stuart Alan S. McNeill. "Prostate Benign Prostatic Hyperplasia." In Blandy's Urology, 531–61. Chichester, UK: John Wiley & Sons, Ltd, 2019. http://dx.doi.org/10.1002/9781118863343.ch27.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Borchers, H., and G. Jakse. "Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia." In Benign Prostatic Hyperplasia, 56–65. Berlin, Heidelberg: Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-77480-5_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Riehmann, Morten, and Reginald C. Bruskewitz. "Prostatic Balloon Dilation." In Benign Prostatic Hyperplasia, 167–74. Berlin, Heidelberg: Springer Berlin Heidelberg, 1994. http://dx.doi.org/10.1007/978-3-642-78185-8_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lawson, R. K., M. T. Story, S. C. Jacobs, and F. P. Begun. "Growth factors in benign prostatic hyperplasia." In Prostatic Hyperplasia, edited by R. Ackermann and F. H. Schröder, 73–80. Berlin, Boston: De Gruyter, 1989. http://dx.doi.org/10.1515/9783110847413-008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

DuBeau, Catherine E. "Benign Prostatic Hyperplasia." In Geriatric Medicine, 557–69. New York, NY: Springer New York, 1997. http://dx.doi.org/10.1007/978-1-4757-2705-0_37.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Sotelo, René, Raed A. Azhar, and José Luis Gaona Morales. "Benign Prostatic Hyperplasia." In Prostate Cancer, 49–72. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-05600-5_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Te, Alexis E., and Bilal Chughtai. "Benign Prostatic Hyperplasia." In Male Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia, 191–200. Chichester, UK: John Wiley & Sons, Ltd, 2014. http://dx.doi.org/10.1002/9781118437889.ch16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Powley, Gina M., and Gail M. Briolat. "Benign Prostatic Hyperplasia." In The Nurse Practitioner in Urology, 119–31. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-45267-4_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Briolat, Gail M. "Benign Prostatic Hyperplasia." In The Nurse Practitioner in Urology, 117–26. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-28743-0_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Mallhi, Tauqeer Hussain, Erum Ijaz, Muhammad Hammad Butt, Yusra Habib Khan, Shahid Shah, Kanwal Rehman, Muhammad Salman, et al. "Benign Prostatic Hyperplasia." In Handbook of Medical and Health Sciences in Developing Countries, 1–19. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-030-74786-2_87-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Benign prostatic hyperplasia"

1

Valvano, Jonathan W., David Y. Yuan, Eric N. Rudie, and Steven J. Clark. "Treatment of Benign Prostatic Hyperplasia." In ASME 1996 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 1996. http://dx.doi.org/10.1115/imece1996-0741.

Full text
Abstract:
Abstract The treatment of benign prostatic hyperplasia (BPH) has implications which affect the majority of the adult male population. Although benign compared to prostate cancer, clinical symptoms can dramatically alter the quality of life. The hyperplastic tissue can cause constriction of the urethra and thus affect voiding of urine. Factors to consider for thermally-based treatments of the prostate include minimization of thermal injury to the urethra and rectum, and maximal delivery of thermal energy to target tissue. Minimizing temperature rise in the urethra allows for minimal or no anesthesia, and has been shown to reduce postoperative complications. Protection of the rectal wall is imperative since injury can lead to clinical complications as severe as a rectal fistula. Due to its location immediately dorsal to the prostate, the ventral aspect of the rectal wall is susceptible to overheating when a uniform radiating microwave heat source is applied transurethrally to treat the prostate. This paper summarizes the engineering technology. numerical modeling, and clinical results to date.
APA, Harvard, Vancouver, ISO, and other styles
2

Chinn, Daniel, Elvis Nditafon, Alvin Yew, and Chandrasekhar Thamire. "Thermal Therapy Protocols for Benign Prostatic Hyperplasia." In ASME 2007 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2007. http://dx.doi.org/10.1115/sbc2007-176764.

Full text
Abstract:
Thermal therapy for treatment of benign prostatic hyperplasia (BPH) is becoming increasingly popular due to the minimally invasive nature of the treatment. Successful management of such therapy requires accurate estimation of thermal dosage. The purpose of this study is to provide correlations for the thermal damage caused by ultrasound, microwave, and infrared devices under a range of operating conditions. A boundary-fitting finite difference method is used to examine the heat transfer in the prostate gland and surrounding tissue. The Pennes bioheat transfer model and a porous media model were utilized to calculate temperature histories. Necrosis zones were determined using published necrosis data for prostatic tissue and cells. Thermal damage correlations for the three different hyperthermia sources along with sample temperature contours and necrosis zones are presented. Results indicate that the applicator power level and heating time are the most important parameters in achieving the desired necrosis zones, while coolant parameters strongly affect the temperatures of the sensitive urethra and serve as constraints for protocol parameters. Out of the three sources evaluated, ultrasound modality appears to be the most capable of causing necrosis in the target zones, with least damage to the surrounding healthy tissues.
APA, Harvard, Vancouver, ISO, and other styles
3

Thamire, Chandrasekhar, and Sharath Bellary. "A Numerical Study of Microwave Thermotherapy for Benign Prostatic Hyperplasia." In ASME 2003 Heat Transfer Summer Conference. ASMEDC, 2003. http://dx.doi.org/10.1115/ht2003-47505.

Full text
Abstract:
Transurethral resection of the prostate is the conventional therapy used for relieving bladder-outflow obstruction that typically occurs in older men due to benign prostatic hyperplasia (BPH). Due to the complications and side effects involved, other therapies that are less invasive have been in use over the last few years. The current study examines one such therapy, namely, the transurethral thermal therapy, and its effectiveness as a treatment modality for BPH. The system considered here is capable of delivering microwave energy preferentially into the prostatic tissue. The heat generated inductively increases the temperature of the tissue to well above 40°C and causes necrosis when applied for adequate times. As both heating times and temperatures dictate the process, a transient analysis of the Pennes bio-heat transfer equation was performed for applicable parameter values. Based on the calculated temperature distributions, necrosis zones are estimated using the existing cell-death data and possible heating protocols are suggested.
APA, Harvard, Vancouver, ISO, and other styles
4

Bryant, Richard, and Robert Van den Heuvel. "Novel therapeutic targets for benign prostatic hyperplasia." In 37th Annual EAU Congress, edited by Rachel Giles. Baarn, the Netherlands: Medicom Medical Publishers, 2022. http://dx.doi.org/10.55788/e481f274.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

McNicholas, Thomas A., and Mohammed Alsudani. "Interstitial laser coagulation therapy for benign prostatic hyperplasia." In Photonics West '96, edited by R. Rox Anderson. SPIE, 1996. http://dx.doi.org/10.1117/12.240022.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Muschter, Rolf. "Laser-induced interstitial thermotherapy of benign prostatic hyperplasia and prostate cancer." In International Symposium on Biomedical Optics Europe '94, edited by Stephen G. Bown, J. Escourrou, Frank Frank, Herbert J. Geschwind, Guilhem Godlewski, Frederic Laffitte, and Hans H. Scherer. SPIE, 1994. http://dx.doi.org/10.1117/12.197575.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Thamire, Chandrasekhar, Rabee Zuberi, Charlie Choe, and Prabhakar Pandey. "Treatment Planning for Transurethral and Interstitial Thermal Therapy for Benign Prostatic Hyperplasia." In ASME 2009 International Mechanical Engineering Congress and Exposition. ASMEDC, 2009. http://dx.doi.org/10.1115/imece2009-10903.

Full text
Abstract:
The purpose of this study is to develop thermal-damage correlations for transurethral and interstitial thermotherapy to aid treatment planning for benign prostatic hyperplasia (BPH). Using an Alternating-direction implicit method, the Pennes bioheat transfer equation is solved for microwave and ultrasound hyperthermia applicators for a range of parameters, including the applicator power, treatment time, and coolant parameters. Thermal coagulation contours are developed by evaluating the temperature-history data against the thermal-damage data obtained in ex-vivo experiments for prostate tissue slices and cells. Treatment protocols are proposed for treatment planning purposes and developing an optimal hyperthermia applicator that can coagulate the target tissue effectively, without destroying the surrounding healthy tissue.
APA, Harvard, Vancouver, ISO, and other styles
8

Zhu, Liang, Zhengxin Mi, and Lisa X. Xu. "Temperature Distribution in Prostate During Transurethral Radio Frequency Thermotherapy Treatment of Benign Prostatic Hyperplasia." In ASME 1998 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 1998. http://dx.doi.org/10.1115/imece1998-0806.

Full text
Abstract:
Abstract The heating pattern of a radio frequency (RF) electrode catheter and its induced temperature field in prostate during transurethral thermal therapy treatment were investigated in this study. Experiments were performed in a tissue-equivalent phantom gel to quantitatively examine the volumetric heating produced by a RF electrode catheter for transurethral prostatic thermotherapy. The specific absorption rate (SAR) of RF energy in the gel was measured from the initial transient temperatures at various locations within the gel. An expression for the SAR was proposed and its unknown parameters in this expression were determined by comparing the predicted and measured SAR values. The SAR distribution was then used in conjunction with the Pennes bioheat transfer equation to model the temperature field in prostate during the thermotherapy treatment. The prostatic tissue temperature rise and its relation to the effect of blood perfusion were analyzed. Blood perfusion is found to be an important factor for removal of heat especially at the higher RF heating level. The minimum RF power required to achieve a maximum tissue temperature above 45 °C is in the range from 14 W to 60 W depending on the local blood perfusion rate (0.2 ∼ 1.5 ml/gm/min). An empirical expression for the detailed temperature field within the prostate for various blood perfusion rates and RF power levels was also provided for clinical purposes.
APA, Harvard, Vancouver, ISO, and other styles
9

Young, Sheunn-Tsong, and Jen-Long Hwang. "Multipoint applicator for thransurethral hyperthermia of benign prostatic hyperplasia." In 1992 14th Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE, 1992. http://dx.doi.org/10.1109/iembs.1992.5760947.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Sheunn-Tsong Young and Jen-Long Hwang. "Multipoint Applicator For Thransurethral Hyperthermia Of Benign Prostatic Hyperplasia." In Proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE, 1992. http://dx.doi.org/10.1109/iembs.1992.589683.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Benign prostatic hyperplasia"

1

Sciacqua, Lucilla Violetta, Andrea Vanzulli, Rosario Di Meo, Giuseppe Pellegrino, Roberto Lavorato, Giovanni Vitale, and Gianpaolo Carrafiello. Minimally invasive treatment in Benign Prostatic Hyperplasia (BPH). INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, December 2022. http://dx.doi.org/10.37766/inplasy2022.12.0004.

Full text
Abstract:
Condition being studied: Review efficacy and safety of minimally-invasive treatments for Low Urinary Tract Symptoms (LUTS) in patients affected by Benign Prostate Hyperplasia (BPH). These minimally invasive techniques represent a valid alternative for patients who can no longer continue medical therapy or are ineligible to surgery. Eligibility criteria: The inclusion criteria concern the most relevant clinical trials on minimally invasive interventions for Benign Prostatic Hyperplasia (BPH) from January 1993 to January 2022.
APA, Harvard, Vancouver, ISO, and other styles
2

Gradinarska, Desislava, Maria Ivanova, Miroslav Genov, Tsvetan Tsvetkov, and Denica Daskalova. Comparative Assay of Seminal-plasma Proteins in Healthy Dogs and Dogs with Benign Prostatic Hyperplasia. "Prof. Marin Drinov" Publishing House of Bulgarian Academy of Sciences, August 2019. http://dx.doi.org/10.7546/crabs.2019.08.17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Wang, Jiaze, Tingting Deng, Hao Sun, Xiaolu Sun, Yuwei You, Ying Wang, Qi Xun, and Yuxia Ma. Efficacy and safety of moxisibostion for benign prostatic hyperplasia: a protocol of systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, December 2021. http://dx.doi.org/10.37766/inplasy2021.12.0021.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Chen, Feng, Yijin Chen, Yongsheng Zou, Yunxiao Wang, Xiaogang Wu, and Milian Chen. Comparison of holmium laser enucleation of prostate and transurethral resection of prostate in patients with benign prostatic hyperplasia: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2023. http://dx.doi.org/10.37766/inplasy2023.5.0065.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

London, Richard A., and Mark Byrne. Optimization of Diode Laser System to Treat Benign Prostate Hyperplasia Final Report CRADA No. TSB-1154-95. Office of Scientific and Technical Information (OSTI), January 2018. http://dx.doi.org/10.2172/1418927.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

London, R. Optimization of Diode Laser System to Treat Benign Prostate Hyperplasia Final Report CRADA No. TSB-1154-95. Office of Scientific and Technical Information (OSTI), January 1998. http://dx.doi.org/10.2172/8426.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

London, R. Optimization of Diode Laser System to Treat Benign Prostate Hyperplasia Final Report CRADA No. TSB-1154-95. Office of Scientific and Technical Information (OSTI), August 2000. http://dx.doi.org/10.2172/773232.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Benign prostatic hyperplasia' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography